FADS2 and cholangiocarcinoma: However, FADS2 mRNA expression was markedly reduced in kidney chromophobe (KICH), cholangiocarcinoma (CHOL), prostate adenocarcinoma (PRAD), kidney renal papillary cell carcinoma (KIRP), and pheochromocytoma and paraganglioma (PCPG) (Fig. 1B).